BIOMARKER:

CREBBP mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

CREBBP mutation	Bladder Cancer	CREBBP mutation	Bladder Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CREBBP mutation	Diffuse Large B Cell Lymphoma	CREBBP mutation	Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
CREBBP mutation	Colorectal Cancer	CREBBP mutation	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
CREBBP mutation	Colorectal Cancer	CREBBP mutation	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
CREBBP mutation	Diffuse Large B Cell Lymphoma	CREBBP mutation	Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: C3 – Early Trials R-CHOP Sensitive : C3	R-CHOP Sensitive: C3 – Early Trials R-CHOP Sensitive : C3
CREBBP mutation	Follicular Lymphoma	CREBBP mutation	Follicular Lymphoma	YF2 Sensitive: D – Preclinical YF2 Sensitive : D	YF2 Sensitive: D – Preclinical YF2 Sensitive : D
CREBBP mutation	Triple Negative Breast Cancer	CREBBP mutation	Triple Negative Breast Cancer	CDK6 inhibitor Sensitive: D – Preclinical CDK6 inhibitor Sensitive : D	CDK6 inhibitor Sensitive: D – Preclinical CDK6 inhibitor Sensitive : D
CREBBP mutation	Triple Negative Breast Cancer	CREBBP mutation	Triple Negative Breast Cancer	CDK4 inhibitor Sensitive: D – Preclinical CDK4 inhibitor Sensitive : D	CDK4 inhibitor Sensitive: D – Preclinical CDK4 inhibitor Sensitive : D